中科微点-全球专利检索

  1. Login
  2. Sign Up
Invention Publication
CN103655552A ManzamenoneO在治疗胰腺癌药物中的应用 失效 - 权利终止 转让

  • Patent Title: ManzamenoneO在治疗胰腺癌药物中的应用
  • Patent Title (English): Application of Manzamenone O in pancreas cancer treatment medicines
  • Application No.: CN201310643422.6
    Application Date: 2013-12-04
  • Publication No.: CN103655552A
    Publication Date: 2014-03-26
  • Inventor: 陈军
  • Applicant: 常州科立信医疗器械有限公司
  • Applicant Address: 江苏省常州市武进经济开发区西太湖国际智慧园4号楼西-256-1
  • Assignee: 常州科立信医疗器械有限公司
  • Current Assignee: 滨州医学院
  • Current Assignee Address: 江苏省常州市武进经济开发区西太湖国际智慧园4号楼西-256-1
  • Main IPC: A61K31/365
  • IPC: A61K31/365 ;  A61P35/00
ManzamenoneO在治疗胰腺癌药物中的应用
Abstract:
本发明公开了Manzamenone O在治疗胰腺癌药物中的应用，属于药物新用途技术领域。本发明通过体外MTT抗肿瘤活性评价发现，Manzamenone O对人胰腺癌细胞株PANC-1和BXPC-3的生长也具有显著的抑制作用。因此，Manzamenone O能用于制备抗胰腺癌药物，具有良好的开发应用前景。对于本发明涉及的Manzamenone O在制备治疗胰腺癌药物中的用途属于首次公开，而且其对于胰腺癌细胞的抑制活性强，具有显著的进步。
Abstract(English):

The invention discloses an application of Manzamenone O in pancreas cancer treatment medicines, and belongs to the technical field of new uses of medicines. An in-vitro MTT antitumor activity evaluation result shows that the Manzamenone O has a substantial inhibition effect on the growth of human pancreas cancer cell strains PANC-1 and BXPC-3, so the Manzamenone O can be used for preparing pancreas cancer resistance medicines, and has a good exploitation application prospect. The use of the Manzamenone O in the preparation of the pancreas cancer treatment medicines is disclosed for the first time. The Manzamenone O has a strong inhibition activity against pancreas cancer cells, and has a substantial progress.

Public/Granted literature
Patent Agency Ranking
0/0